Oxidative cyclodehydrogenation is an important process in the formation of the new graphene, N-(1)/(2)HSB 2. This heteropolyaromatic results from the FeCl(3)-catalyzed oxidative cyclodehydrogenation of 1,2-dipyrimidyl-3,4,5,6-tetra-(4-tert-butylphenyl)benzene. Three new C-C bonds are formed that lock the two pyrimidines in a molecular platform comprising eight fused aromatic rings flanked by two remaining "uncyclized" phenyl rings. Mechanistically intriguing is the fact that N-HSB 1, the product of six C-C bond fusions, is co-synthesized with its "half-cyclized" daughter in this reaction. 1 and 2 have the same bidentate N-atom arrangement. This facilitates formation of the heteroleptic Ru(II) complexes, [Ru(bpy)(2)(2)](PF(6))(2) 4 and [Ru(bpy)(2)(1)](PF(6))(2) 3, which differ in the size and planarity of their aromatic ligands. The new ligand 2 and its complex 4 are characterized by (1)H NMR, IR, ESI-MS, and accurate mass methods. 2 exhibits photophysical properties that are consistent with a reduction of the pi/pi framework, a concomitant increase in the energy of the LUMO, and a blue-shift of the solvent-dependent fluorescence (lambda(em) = 474 nm, phi(F) = 0.55, toluene) as compared to its parent. Complex 4 absorbs throughout the visible region and borders on near-IR emitter character, exhibiting a slightly blue-shifted (3)MLCT emission (868 nm, CH(3)CN) as compared to that of [Ru(bpy)(2)(1)](PF(6))(2) 3 (880 nm, CH(3)CN). Electrochemical analyses permit further elucidation of the intermolecular interactions of 3 and 4. These and the concentration and temperature-dependent NMR spectra of 4 confirm it to be nonaggregating, a direct result of the two uncyclized and rotatable phenyl rings in 2.
No takes yet. Share an insight, caveat, or question.
Gregg et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: